Search results

Sort By:

Limit search:

The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience

100%

Kardas J., Buraczewska A., Chrom P., Waśko-Grabowska A., Młot B., Szczylik C.

OncoReview

2017

vol. 7

issue 2

92-97

Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.

Refine search results

1 OncoReview

1 2017

1 Buraczewska A.

1 Chrom P.

1 Kardas J.

1 Młot B.

1 Szczylik C.

1 Waśko-Grabowska A.

Search results

The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience